Preeclampsia as a Cardiovascular Diagnosis: A Pregnancy Complication That Forecasts the Heart

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Preeclampsia is treated as an obstetric event: it complicates a pregnancy, it is managed, the baby is delivered, and the file closes. The cardiovascular evidence says that file should never fully close. A history of preeclampsia is one of the most consistently documented sex-specific predictors of future cardiovascular disease, and it belongs in a woman’s heart risk assessment for the rest of her life.

The magnitude of the risk

The association is well quantified. 5 / Solid A systematic review and meta-analysis found that a history of preeclampsia is associated with roughly a doubling of later cardiovascular disease risk, including coronary heart disease, and with elevated risk of stroke and hypertension over subsequent years and decades (Bellamy et al, BMJ 2007). The effect persists after accounting for shared risk factors, marking preeclampsia as more than a coincidental flag.

This is why major prevention guidance recognizes hypertensive disorders of pregnancy as cardiovascular risk enhancers that can inform prevention decisions, including the timing and intensity of risk-factor management.

The proposed mechanisms

Two non-exclusive explanations are advanced, and both are plausible. 3 / Early First, preeclampsia may unmask a pre-existing cardiovascular and vascular susceptibility, with pregnancy serving as a stress test that reveals limited reserve. Second, the endothelial and vascular injury of preeclampsia itself may contribute to later disease. The relative contribution of unmasking versus injury is not settled, which is why the mechanism carries an early rating, but the predictive value does not depend on resolving it.

How it should change care

A history of preeclampsia argues for earlier and closer cardiovascular surveillance than age-based risk alone would dictate: ongoing blood-pressure monitoring, since the history raises the risk of chronic hypertension even after postpartum normalization, and periodic assessment of lipids and glucose. 4 / Promising It strengthens the case for early lifestyle prevention and can tip borderline treatment decisions. The intervention window opens after the pregnancy and runs for decades, which is precisely the window most often left unmanaged.

What this means

Preeclampsia roughly doubles a woman’s later cardiovascular risk, a finding solid enough to act on regardless of the unsettled mechanism. The failure is not in the science but in the handoff: the diagnosis stays in the obstetric record and never reaches cardiovascular care. Carrying it forward, and counting it as a risk enhancer, converts a closed pregnancy complication into an open and persistent cardiovascular warning.

The biology of preeclampsia: what happens in the placenta and what it predicts

Preeclampsia is not simply high blood pressure in pregnancy. It is a disorder rooted in abnormal placentation, the process by which the placenta establishes its blood supply, and the vascular consequences of that abnormality reach far beyond the uterus. 4 / Promising

In normal early pregnancy, fetal trophoblast cells invade the uterine spiral arteries and remodel them from narrow, high-resistance vessels into wide, low-resistance conduits capable of sustaining the blood flow demands of a growing fetus. In pregnancies that develop preeclampsia, this remodeling is shallow or incomplete. The spiral arteries remain narrow and high-resistance, placental perfusion is inadequate, and the placenta responds by releasing factors into the maternal circulation that, through unclear but probably compensatory mechanisms, profoundly disturb maternal vascular function.

The most studied of these factors are soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). sFlt-1 is a decoy receptor for vascular endothelial growth factor (VEGF) and PlGF: it binds and sequesters these pro-angiogenic molecules before they can act on blood vessel walls, depleting them from the circulation. The result is systemic endothelial dysfunction. Blood vessels throughout the mother’s body lose the normal angiogenic maintenance that VEGF provides. They become leaky, vasoconstrictive, and inflamed. Blood pressure rises, kidneys leak protein, and in severe cases, the liver, brain, and clotting system are affected.

The sFlt-1 to PlGF ratio has emerged as a clinically useful biomarker for predicting and diagnosing preeclampsia, and research shows that this ratio begins to shift weeks before clinical preeclampsia manifests. What this biology implies for long-term risk is that a woman who developed preeclampsia had, during that pregnancy, sustained systemic endothelial insult at a level sufficient to impair organ function. Whether she entered the pregnancy with vascular susceptibility that was then revealed, or whether the placental-derived insult itself damaged her vasculature beyond what recovered postpartum, or both, the vascular system she carries forward is not the same as one that was never exposed to that sFlt-1 excess.

The spectrum: gestational hypertension, preeclampsia, severe features, and HELLP

Not all hypertensive pregnancy complications carry identical long-term cardiovascular implications, though the literature supports elevated risk across the spectrum. 4 / Promising

Gestational hypertension, defined as new-onset hypertension in pregnancy without proteinuria or end-organ involvement, is associated with elevated later cardiovascular risk, though the magnitude is generally lower than for preeclampsia with severe features. Preeclampsia with severe features, defined by systolic blood pressure at or above 160 mmHg or diastolic at or above 110 mmHg, or end-organ evidence including severe headache, visual changes, elevated liver enzymes, severe thrombocytopenia, or severe renal impairment, carries greater vascular insult than preeclampsia without severe features.

HELLP syndrome, standing for Hemolysis, Elevated Liver enzymes, and Low Platelets, represents a severe systemic manifestation of the same placental-origin process. Women who experienced HELLP have the highest rates of subsequent hypertension and carry substantial long-term cardiovascular risk.

The risk gradient matters for surveillance intensity. A woman whose pregnancy was complicated by preeclampsia without severe features who normalized her blood pressure promptly postpartum faces a different monitoring interval than one whose pregnancy was complicated by HELLP with persistent hypertension into the postpartum period. Both carry elevated lifetime risk; the degree of clinical aggressiveness in follow-up should reflect the severity of the original presentation.

Updated meta-analytic estimates: refining the risk picture

The Bellamy et al. meta-analysis in BMJ 2007 established the foundational risk estimates, but subsequent analyses refined and extended those figures with longer follow-up and larger samples. Grandi and colleagues published an updated meta-analysis examining these associations with attention to specific cardiovascular outcomes and their timing. 5 / Solid

Across large pooled analyses, the relative risk for coronary heart disease after preeclampsia is approximately two-fold elevated compared with normotensive pregnancy, consistent across studies. For stroke, the relative risk is similarly elevated, in the range of 1.8 to 2.5 in most analyses. The risk for development of chronic hypertension is particularly striking: women with a history of preeclampsia have approximately a three- to four-fold elevated risk of chronic hypertension compared with women whose pregnancies were normotensive, and this risk materializes over a compressed timeline of years rather than decades.

Heart failure risk is also elevated, with some analyses finding a two- to three-fold higher rate in women with preeclampsia history. These heart failure events are not confined to later decades; excess risk appears within the first decade after the affected pregnancy in some datasets. The cardiovascular risk elevation from preeclampsia thus cuts across multiple organ systems, affects multiple outcome types, and begins relatively soon after the pregnancy rather than being confined to remote decades.

Preterm versus term preeclampsia: does timing matter?

The distinction between preeclampsia presenting before 37 weeks of gestation and that presenting at or after 37 weeks is clinically and prognostically relevant. 4 / Promising

Preterm preeclampsia is generally considered to reflect more severe placental dysfunction. The placenta was unable to sustain adequate perfusion through a full-term pregnancy, and delivery before term was required for maternal or fetal safety. Observational data consistently show that preterm preeclampsia is associated with higher long-term cardiovascular risk than term preeclampsia. Some analyses have found the relative risk for coronary heart disease and stroke to be substantially higher in women whose preeclampsia was preterm, with risk approaching three- to four-fold in some cohorts, compared with approximately two-fold in term preeclampsia.

This distinction should influence how urgently follow-up is initiated and how aggressively risk factors are managed in the postpartum period. A woman with preterm preeclampsia, particularly if it was accompanied by severe features, should be on a short interval for blood pressure monitoring and cardiovascular assessment in the postpartum year. She represents a higher-priority case for early preventive engagement than the overall preeclampsia statistics alone would convey.

The hypertension trajectory after preeclampsia

Among the several long-term consequences of preeclampsia, the development of chronic hypertension is the most well-documented and the one that materializes most quickly. Blood pressure often normalizes within the first twelve weeks after delivery, which is the basis for distinguishing preeclampsia from chronic hypertension, but normalization at twelve weeks does not mean the risk of eventual hypertension is resolved. 5 / Solid

Large cohort studies show that within five to ten years of a preeclamptic pregnancy, a substantial proportion of affected women, in some cohorts approaching 15 to 20 percent, have developed sustained chronic hypertension. By middle age, the cumulative proportion with hypertension is substantially higher than in women with normotensive pregnancies matched for baseline characteristics. The hypertension that develops is not merely a carry-over of elevated pregnancy blood pressure; it is new, chronic hypertension in women whose postpartum blood pressure had normalized.

The clinical implication is a specific monitoring protocol. Blood pressure should be measured at the six-week postpartum visit and at each subsequent well-woman visit, with deliberate attention to trends rather than single values. A woman whose blood pressure is 120/80 at six weeks postpartum should still have it measured annually, because the trajectory over the subsequent years matters more than any single postpartum measurement. If hypertension develops, treatment thresholds and targets are the same as in the general population, but the cardiovascular context, a woman with already-elevated baseline cardiovascular risk, strengthens the case for treating rather than watching.

Lipid changes and when to reassess

Preeclampsia is associated with a proatherogenic lipid profile during and after the affected pregnancy. During preeclampsia, triglycerides are substantially elevated and HDL cholesterol is reduced, a pattern consistent with underlying insulin resistance and endothelial dysfunction. The question is how much of this lipid pattern persists after the pregnancy. 3 / Early

Studies comparing women with prior preeclampsia to matched controls in the years after pregnancy show that the preeclampsia group tends to have higher LDL cholesterol, lower HDL cholesterol, and higher triglycerides compared to normotensive controls, even years after the pregnancy. Whether this represents pre-existing dyslipidemia unmasked by pregnancy stress or a persisting metabolic consequence of the pregnancy is unclear, but the practical question is the same: lipids should be measured in the postpartum period and reassessed at the intervals used for cardiovascular risk monitoring.

Current cardiovascular prevention guidelines do not specify a unique lipid-reassessment schedule for preeclampsia survivors, but the context supports not waiting for age-based thresholds. A fasting lipid panel at the first cardiovascular visit after preeclampsia, and then at two- to three-year intervals or more frequently if values are trending toward treatment thresholds, is a reasonable approach given the known risk elevation.

The AHA and ACC 2019 primary prevention guidelines: what was incorporated

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly included hypertensive disorders of pregnancy, specifically preeclampsia, as a risk-enhancing factor that clinicians should consider when making treatment decisions in patients who are at intermediate cardiovascular risk by standard pooled cohort equation calculations. 5 / Solid

Risk-enhancing factors in that guideline framework are conditions or history items that, when present, tip the scale toward earlier or more intensive preventive treatment in patients whose pooled cohort equation score places them in a borderline or intermediate zone where the decision to initiate a statin or aspirin is otherwise uncertain. The formal inclusion of preeclampsia in this framework represents the first time a major joint society primary prevention guideline made this association explicit and placed it in the clinical decision algorithm.

This is not a trivial policy detail for the women affected. It means that a 45-year-old woman whose ten-year cardiovascular risk score by the pooled cohort equation is 7.5 percent, a borderline zone where statin initiation is discussed rather than automatic, has a meaningful risk-enhancing factor in her preeclampsia history that should move that conversation toward treatment rather than watchful waiting. Without the guideline provision, that history would likely not be part of the calculation.

The postpartum care gap: what is documented and what it costs

The gap between what the science recommends and what women with preeclampsia actually receive in postpartum follow-up is well-documented and substantial. Studies examining postpartum care patterns show that most women with preeclampsia do not receive formal cardiovascular risk counseling before hospital discharge, most primary care providers are not aware of the long-term cardiovascular risk associated with the diagnosis, and the obstetric record rarely communicates the preeclampsia history to subsequent primary care or cardiology providers. 4 / Promising

A study examining postpartum outcomes after preeclampsia found that fewer than half of women with preeclampsia received blood pressure follow-up within three months of delivery, despite the well-established near-term risk of developing chronic hypertension in that window. The six-week postpartum visit, already incompletely attended, is the only standard touchpoint where cardiovascular follow-up might be initiated, and blood pressure measurement at that visit is often not linked to any longer-term surveillance plan.

The cost of this gap is not theoretical. Each year of undetected hypertension in a woman with already-elevated cardiovascular risk represents compounding vascular exposure. A woman with preeclampsia history who develops hypertension at age 38 but is not diagnosed until age 44 carries six years of untreated hypertension that accelerate the atherosclerotic process the preeclampsia had already set in motion. The science describing the risk is more than adequate. The care system to act on it is not.

What to tell the cardiologist and what to ask

A woman with a history of preeclampsia attending a cardiovascular visit, whether at age thirty-five or fifty-five, should state that history explicitly at intake and confirm it was heard and recorded. It should appear in her cardiovascular problem list, not buried in an obstetric history that most cardiovascular intake forms do not ask about.

The questions that deserve direct answers at a cardiovascular visit with a preeclampsia history include: what her ten-year cardiovascular risk score is with the preeclampsia history counted as a risk-enhancing factor, what her blood pressure trajectory has been since the affected pregnancy, when her lipids were last measured, and what the threshold is for initiating a statin or aspirin given her specific combination of risk factors.

She should ask whether she should have baseline cardiac imaging, since some centers perform coronary artery calcium scoring or other risk stratification in women with strong risk-enhancing factors to inform treatment decisions. She should understand the blood pressure targets that apply to her, since for women with preeclampsia history, treating to a lower target earlier may be clinically justified.

She should confirm the surveillance interval: when will blood pressure be rechecked, when will lipids be reassessed, and who is responsible for that follow-up. The postpartum care gap persists in part because the answer to that question is often unclear, with obstetricians considering it a primary care task and primary care providers unaware of the urgency. Naming a responsible clinician and a specific timeline before leaving the visit is the most concrete protection against the gap.